CRISPR Therapeutics AG (NASDAQ:CRSP) Morgan Stanley 20th Annual Global Healthcare Conference Call September 12, 2022 11:40 AM ET Company Participants Samarth Kulkarni - Chief Executive Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Okay, great. Thanks for joining us, everybody. I’m Terence Flynn, Morgan Stanley, pharma and biotech analyst, and we’re very pleased to be hosting CRISPR Therapeutics this morning. First, for important disclosures, please see the Morgan Stanley ...

© 2022 CRISPR Therapeutics 1 Creating transformative gene-based medicines for serious diseases Corporate Overview | Q3 2022 Forward-Looking Statements The presentation and other related materials may contain a number of "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding CRISPR Therapeutics' expectations about any or all of the following: (i) its plans and expectations for its preclinical studies, clinical trials ...

CRISPR Therapeutics AG (NASDAQ:CRSP) Citi 17th Annual BioPharma Conference September 7, 2022 8:50 AM ET Company Participants Sam Kulkarni – Chief Executive Officer Conference Call Participants Yigal Nochomovitz – Citi Yigal Nochomovitz All right, well, welcome everyone. I’m Yigal Nochomovitz, one of the biotech analysts here at Citi. It's my great pleasure and privilege to have with me, the CEO of CRISPR Therapeutics, Sam Kulkarni. Welcome. Sam Kulkarni Thank you, Yigal for having us. Yigal Nochomovitz Grea ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37923 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland Not Applicable (State or other jurisdicti ...

CRISPR Therapeutics AG (NASDAQ:CRSP) Innovation Day Conference Call June 21, 2022 2:00 PM ET Company Participants Samarth Kulkarni - Chief Executive Officer Phuong Khanh Morrow - Chief Medical Officer Sumanta Kumar Pal - Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research, Co-Director, Kidney Cancer Program, City of Hope Susan Kim - Vice President of Corporate Communications & Investor Relations Jon Terrett - Head of Research Swaminathan Iyer - Professor, Department of Lymph ...

Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease Franco Locatelli, 1 Haydar Frangoul,2 Selim Corbacioglu,3 Josu de la Fuente,4 Donna Wall,5 Maria Domenica Cappellini,6 Mariane de Montalembert,7 Antonis Kattamis,8 Stephan Lobitz,9 Damiano Rondelli,10 Sujit Sheth,11 Martin Steinberg,12 Mark C. Walters,13 Yael Bobruff,14 Chris Simard,14 Yang Song,14 Lanju Zhang,14 Anjali Sharma,15 Suzan Imren,14 Bill Hobbs,14 Stephan Grupp16 ...

CRISPR Therapeutics AG (NASDAQ:CRSP) Goldman Sachs 43rd Annual Global Healthcare Conference June 15, 2022 12:20 PM ET Company Participants Lawrence Klein - Chief Operating Officer Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Good morning, everyone. Thanks for joining us. We're really pleased to have CRISPR Therapeutics here and with us, we have Lawrence Klein, COO. Question-and-Answer Session Q - Salveen Richter To start, Lawrence, you're hosting an Innovation Day on June 21 ...

® © 2021 CRISPR Therapeutics 1 CRISPR Creating transformative gene-based medicines for serious diseases Corporate Overview | Q2 2022 Forward-Looking Statements The presentation and other related materials may contain a number of "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding CRISPR Therapeutics' expectations about any or all of the following: (i) the safety, efficacy and clinical progress of our various clin ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37923 CRISPR THERAPEUTICS AG (Exact name of Registrant as specified in its charter) Switzerland Not Applicable (State or other jurisdict ...

CRISPR Therapeutics AG (NASDAQ:CRSP) Barclays Global Healthcare Conference Call March 17, 2022 10:15 AM ET Company Participants Sam Kulkarni - Chief Executive Officer Conference Call Participants Gena Wang - Barclays Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are designed to help you navigate the audio should the corresponding text be unclear. The machine-assisted output provided is partly edited and is de ...